For Patients
Find essential information here about ovarian cancer prevention, risk factors, and steps to take if you’ve been newly diagnosed, in treatment or navigating life beyond.
The Clearity Foundation Has Joined OCRA
Together, we’re expanding support, education, and resources for the gynecologic cancer community.
Strengthening Support Through Partnership
Ovarian Cancer Research Alliance (OCRA), the world’s leading ovarian and gynecologic cancer nonprofit, is proud to announce that The Clearity Foundation has combined with OCRA. This important development brings together two of the most respected organizations in the ovarian cancer field, combining OCRA’s leading research, advocacy, and patient support programs with Clearity’s focus on scientific education and support for women and families facing an ovarian cancer diagnosis.
Please explore the resources below to learn more about the expanded support and tools now available.
Support & Resources
OCRA is here for you and your family to answer questions or connect you with resources to help you and offer support.
Research
OCRA has awarded more than 400 grants and invested $140 million in ovarian cancer and related gynecologic cancer research initiatives, becoming the largest global charity devoted to ovarian and related gynecologic cancer research in the world.
Center for Public Policy
OCRA advocates on Capitol Hill to improve research and education, drug and diagnostic safety, and access to quality care for all members of the ovarian and gynecologic cancer community, having helped secure $3.8 billion in federal research and education funding since inception..
Get Involved
Help us get one step closer to a cure. There are so many ways to lend a hand and improve the lives of patients and families impacted by ovarian and all gynecologic cancers.
About
OCRA is the leading organization in the world fighting ovarian and all gynecologic cancers on all fronts while supporting patients and their families.
Related Topics
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
The Overview: March 2026
OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued